Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2026Journal of Cardiac FailureOpen Access

High cDPP3 before VA-ECMO is linked to ~313% higher 30-day mortality in cardiogenic shock.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Prognostic properties of cDPP3 had not yet been investigated in the most severe CS patients requiring VA-ECMO.

Is high cDPP3 concentration before VA-ECMO implantation associated with worse 30-day survival and organ dysfunction in patients with cardiogenic shock?

Population

47 patients with CS receiving VA-ECMO

Comparison

Patients with cDPP3 >73 ng/mL vs lower cDPP3 concentrations at VA-ECMO implantation

Design

Post hoc analysis of a prospective cohort study

Follow-up

30 days

Key result

High cDPP3 concentrations (>73 ng/mL) before VA-ECMO implantation in patients with cardiogenic shock were associated with lower 30-day survival (adjusted HR 4.13; 95% CI 1.55-10.98).

Authors

JBJolie BrunoMDManon DurandFAFériel Azibani

Discussion

Loading...

Member takes

Overview

High cDPP3 may flag higher-risk VA-ECMO patients; extends prior prognostic signals to severe CS but leaves clinical utility open.

Key Points

  • To evaluate the prognostic value of circulating dipeptidyl peptidase-3 (cDPP3) concentrations for organ dysfunction and 30-day mortality in patients with severe cardiogenic shock requiring VA-ECMO.
  • Post hoc analysis of the prospective ADRECMO cohort including 47 analyzed patients with cardiogenic shock supported by VA-ECMO.
  • cDPP3 plasma concentrations were quantified prior to VA-ECMO implantation, at day 3 to 5 of support, and immediately before explantation.
  • Associations between cDPP3 levels, organ dysfunction markers, and 30-day survival were assessed, adjusting for shock etiology, implantation timing, and pre-implantation cardiac arrest.
  • Median cDPP3 levels declined significantly during support, from 73 ng/mL (IQR 46–151) at implantation to 47 ng/mL (IQR 30–64) at day 3–5, and 39 ng/mL (IQR 29–50) at explantation (p < 0.001).
  • Patients with baseline cDPP3 >73 ng/mL presented with higher lactate (3.5 vs. 1.9 mmol/L, p < 0.001), lower eGFR (26 vs. 75 mL/min/1.73 m², p < 0.001), elevated AST (1127 vs. 195 IU/L, p < 0.001), and higher cumulative norepinephrine use (682 vs. 93 μg/kg, p = 0.001).
  • Baseline cDPP3 >73 ng/mL independently predicted lower 30-day survival (adjusted HR 4.13, 95% CI 1.55–10.98), whereas cDPP3 concentrations measured at later timepoints showed no significant association with survival.

Study Design

Type

Cohort (n=47)

Structured PICO

Is high cDPP3 concentration before VA-ECMO implantation associated with worse 30-day survival and organ dysfunction in patients with cardiogenic shock?

P
Population
47 patients with cardiogenic shock requiring venoarterial extracorporeal membrane oxygenation, evaluated for 30-day survival.
E
Exposure
High circulating dipeptidyl peptidase-3 (cDPP3) concentrations (>73 ng/mL) before VA-ECMO implantation
C
Comparator
Low cDPP3 concentrations (≤73 ng/mL) before VA-ECMO implantation
O
Outcome
30-day survival and level of organ dysfunctionhard clinical

Main Result

Hazard Ratio: 4.13 (95% CI 1.55–10.98)

High cDPP3 levels before VA-ECMO implantation in cardiogenic shock patients are associated with greater organ dysfunction and significantly lower 30-day survival.

Cite This Study

Bruno et al. (2026) conducted a cohort in Cardiogenic shock requiring VA-ECMO (n=47). High cDPP3 concentrations (>73 ng/mL) vs. Low cDPP3 concentrations was evaluated on 30-day survival (adjusted HR 4.13, 95% CI 1.55-10.98). High cDPP3 concentrations (>73 ng/mL) before VA-ECMO implantation in patients with cardiogenic shock were associated with lower 30-day survival (adjusted HR 4.13; 95% CI 1.55-10.98).

synapsesocial.com/papers/6a826e58ce17449fdfffbcbahttps://doi.org/10.1016/j.cardfail.2026.07.030
View Full Paper
Ask AI
Bookmark
Share